Stryker Corporation has announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Incompass® Total Ankle System. This new implant is designed for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. The Incompass system integrates advanced technologies from Stryker's existing Inbone® and Infinity® systems into a comprehensive solution for total ankle replacement. Developed using the Stryker Orthopaedic Modeling & Analytics (SOMA) platform, the system offers improved surgical flexibility and efficiency, leveraging data from extensive clinical cases and CT scans.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。